Pipeline
Aneira's dual-mechanism pharmacology platform anchors two lead clinical programs, with a disciplined expansion path across additional hair-growth indications. Lead and future programs are at different stages of development.
Lead Programs — Clinical-Stage
The program pairs two established pharmacologies with complementary follicular mechanisms. Early human data are directionally consistent with the dual-mechanism hypothesis and are being advanced into larger controlled studies.
Clinical-stage — Phase 2a signal reported; larger controlled trials in preparation
An early vehicle-controlled human study reported progressive increases in brow fullness over 90 days. The program addresses an area currently served almost entirely by cosmetics.
Clinical-stage — early human signal reported; larger controlled trials in preparation
Future Pipeline — Earlier-Stage Programs
| Program | Area | Indication | Status |
|---|---|---|---|
| ANR-002 | Scalp | Alopecia Areata | Discovery-stage concept |
| ANR-003 | Brow | Eyebrow loss for chemotherapy patients | Discovery-Stage Concept |
| ANR-004 | Eyelash | Eyelash Hypotrichosis | Discovery-stage concept |
| ANR-005 | Facial Hair | Inadequate beard growth | Discovery-stage concept |
Future programs are discovery-stage concepts and do not share the development status of the lead programs. All programs are investigational.
